Unmet Medical Need
Immediate indications are Dravet's Syndrome/Lennox-Gastaut Syndrome (LGS)
Lior Pharma is a company of biopharmaceutical products of initial public offering (IPO) focused on bringing new cannabinoid pharmaceutical products. Its immediate focus is to market 3 main indications of orphan drugs for rare diseases and with the use of its own patented drug delivery system technology. The specific technology of Conjugate Particles (SCP) and targeted cannabinoids are the core of this company at this time.
The SCP technology and its robust development platform has allowed the real delivery of 100% bioavailable and water soluble cannabinoid extracts with their mass and critical size in the systemic circulation and avoid their sequestration by adipose tissues.